Aileron Therapeutics, a US-based biotechnology company, has received the second tranche of its series D round, which has also been extended by $2m to $42m.
The $12m second tranche is for a human study of a stapled peptide.
In June 2009, Roche Venture Fund, the corporate venturing unit of the Swiss group, was part of a consortium, including Lilly Ventures, GlaxoSmithKline’s SR One, and Novartis Venture Funds, that invested $40m in Aileron’s series D round, and $60m in total. The other investors were venture capital firms Apple Tree Partners and Excel Venture Management.